Kruso Kapital S.p.A. (BIT:KK)

Aerovate Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Interest Income on Loans	17.14	15.06	11.18
Interest Paid on Deposits	4.77	4.64	3.75
Net Interest Income	12.37	10.43	7.44
Net Interest Income Growth (YoY)	42.56%	40.27%	-
Other Non-Interest Income	18.06	14.27	11.97
Total Non-Interest Income	18.3	14.27	11.97
Non-Interest Income Growth (YoY)	37.95%	19.21%	-
Revenues Before Loan Losses	30.67	24.7	19.41
Provision for Loan Losses	0.08	0.09	0.07
Revenue	30.59	24.61	19.33
Revenue Growth (YoY)	40.14%	27.30%	-
Salaries and Employee Benefits	9.16	8.56	6.93
Occupancy Expenses	1.17	1.17	1.12
Amortization of Goodwill & Intangibles	0.63	0.63	0.57
Selling, General & Administrative	8.68	7.34	6.33
Other Non-Interest Expense	-0.72	-0.67	-0.18
Total Non-Interest Expense	18.91	17.03	14.77
EBT Excluding Unusual Items	11.68	7.58	4.57
Pretax Income	11.14	7.58	4.57
Income Tax Expense	4.15	3.08	1.68
Net Income	6.99	4.5	2.89
Net Income to Common	6.99	4.5	2.89
Net Income Growth	82.09%	55.98%	-
Basic Shares Outstanding	-	25	-
Diluted Shares Outstanding	-	25	-
EPS (Basic)	-	0.18	-
EPS (Diluted)	-	0.18	-
Effective Tax Rate	37.29%	40.66%	36.80%

Source: S&P Global Market Intelligence. Banks template. Financial Sources.